INmune Other Assets vs Net Working Capital Analysis

INMB Stock

USD 11.29 0.45 4.15%

INmune Bio financial indicator trend analysis is infinitely more than just investigating INmune Bio recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether INmune Bio is a good investment. Please check the relationship between INmune Bio Other Assets and its Net Working Capital accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

Other Assets vs Net Working Capital

Other Assets vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of INmune Bio Other Assets account and Net Working Capital. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between INmune Bio's Other Assets and Net Working Capital is -0.5. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of INmune Bio, assuming nothing else is changed. The correlation between historical values of INmune Bio's Other Assets and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of INmune Bio are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Other Assets i.e., INmune Bio's Other Assets and Net Working Capital go up and down completely randomly.

Correlation Coefficient

-0.5

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Other Assets

Net Working Capital

Most indicators from INmune Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into INmune Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.The current year's Enterprise Value is expected to grow to about 185.9 M, whereas Selling General Administrative is forecasted to decline to about 6.4 M.

	2010	2023	2024 (projected)
Interest Income	77.7K	69.9K	62.2K
Net Interest Income	77.7K	69.9K	62.2K

Interest Income Net Interest Income

INmune Bio fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Net Debt	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Short Long Term Debt	Short Term Debt	Net Invested Capital	Net Working Capital	Intangible Assets	Retained Earnings Total Equity
Total Assets		-0.08	0.6	0.99	0.92	-0.78	0.72	0.98	0.98	0.87	0.88	0.98	0.31	0.92	-0.97	0.9	0.93	0.85	0.12	0.95	0.72	0.43	0.97	0.95	-0.25	-0.86
Other Current Liab	-0.08		-0.24	-0.02	-0.28	0.21	-0.22	-0.26	-0.26	-0.17	-0.28	-0.25	-0.19	-0.29	0.25	-0.23	-0.04	-0.34	0.06	-0.13	0.32	-0.26	-0.28	-0.27	0.18	0.28
Total Current Liabilities	0.6	-0.24		0.54	0.81	-0.96	0.98	0.56	0.56	0.9	0.86	0.57	0.91	0.7	-0.58	0.56	0.74	0.83	-0.13	0.76	0.71	0.98	0.57	0.49	-0.86	-0.9
Total Stockholder Equity	0.99	-0.02	0.54		0.89	-0.74	0.67	0.96	0.96	0.84	0.83	0.96	0.26	0.87	-0.96	0.87	0.91	0.79	0.21	0.92	0.72	0.36	0.95	0.94	-0.22	-0.81
Net Tangible Assets	0.92	-0.28	0.81	0.89		-0.92	0.9	0.92	0.92	0.97	0.96	0.92	0.61	0.91	-0.95	0.8	0.91	0.9	0.03	0.93	0.71	0.69	0.93	0.89	-0.57	-0.94
Retained Earnings	-0.78	0.21	-0.96	-0.74	-0.92		-0.99	-0.74	-0.74	-0.98	-0.94	-0.75	-0.8	-0.82	0.76	-0.71	-0.89	-0.91	0.0	-0.9	-0.79	-0.89	-0.75	-0.68	0.74	0.97
Accounts Payable	0.72	-0.22	0.98	0.67	0.9	-0.99		0.69	0.69	0.96	0.92	0.69	0.86	0.79	-0.71	0.65	0.83	0.88	-0.07	0.85	0.76	0.93	0.7	0.62	-0.81	-0.94
Cash	0.98	-0.26	0.56	0.96	0.92	-0.74	0.69		1.0	0.83	0.88	1.0	0.28	0.94	-0.99	0.89	0.88	0.86	0.06	0.92	0.59	0.4	0.99	0.98	-0.22	-0.84
Cash And Short Term Investments	0.98	-0.26	0.56	0.96	0.92	-0.74	0.69	1.0		0.83	0.88	1.0	0.28	0.94	-0.99	0.89	0.88	0.86	0.06	0.92	0.59	0.4	0.99	0.98	-0.22	-0.84
Capital Surpluse	0.87	-0.17	0.9	0.84	0.97	-0.98	0.96	0.83	0.83		0.96	0.84	0.72	0.87	-0.86	0.78	0.93	0.91	0.05	0.94	0.81	0.8	0.84	0.79	-0.67	-0.97
Total Liab	0.88	-0.28	0.86	0.83	0.96	-0.94	0.92	0.88	0.88	0.96		0.89	0.63	0.96	-0.88	0.86	0.87	0.96	-0.16	0.92	0.67	0.76	0.89	0.85	-0.59	-0.98
Total Current Assets	0.98	-0.25	0.57	0.96	0.92	-0.75	0.69	1.0	1.0	0.84	0.89		0.27	0.95	-0.98	0.92	0.88	0.87	0.04	0.92	0.59	0.41	0.99	0.98	-0.21	-0.85
Common Stock	0.31	-0.19	0.91	0.26	0.61	-0.8	0.86	0.28	0.28	0.72	0.63	0.27		0.41	-0.33	0.18	0.52	0.58	-0.13	0.51	0.62	0.94	0.28	0.2	-0.95	-0.66
Short Long Term Debt Total	0.92	-0.29	0.7	0.87	0.91	-0.82	0.79	0.94	0.94	0.87	0.96	0.95	0.41		-0.91	0.92	0.85	0.95	-0.21	0.91	0.57	0.58	0.95	0.92	-0.34	-0.92
Net Debt	-0.97	0.25	-0.58	-0.96	-0.95	0.76	-0.71	-0.99	-0.99	-0.86	-0.88	-0.98	-0.33	-0.91		-0.86	-0.87	-0.83	-0.12	-0.9	-0.6	-0.42	-0.99	-0.98	0.3	0.84
Net Receivables	0.9	-0.23	0.56	0.87	0.8	-0.71	0.65	0.89	0.89	0.78	0.86	0.92	0.18	0.92	-0.86		0.79	0.85	-0.02	0.85	0.49	0.42	0.92	0.9	-0.16	-0.85
Common Stock Total Equity	0.93	-0.04	0.74	0.91	0.91	-0.89	0.83	0.88	0.88	0.93	0.87	0.88	0.52	0.85	-0.87	0.79		0.89	0.2	0.99	0.88	0.61	0.85	0.8	-0.39	-0.9
Common Stock Shares Outstanding	0.85	-0.34	0.83	0.79	0.9	-0.91	0.88	0.86	0.86	0.91	0.96	0.87	0.58	0.95	-0.83	0.85	0.89		-0.16	0.93	0.67	0.74	0.85	0.79	-0.47	-0.96
Other Current Assets	0.12	0.06	-0.13	0.21	0.03	0.0	-0.07	0.06	0.06	0.05	-0.16	0.04	-0.13	-0.21	-0.12	-0.02	0.2	-0.16		0.11	0.22	-0.19	0.03	0.05	0.13	0.03
Other Stockholder Equity	0.95	-0.13	0.76	0.92	0.93	-0.9	0.85	0.92	0.92	0.94	0.92	0.92	0.51	0.91	-0.9	0.85	0.99	0.93	0.11		0.82	0.63	0.9	0.85	-0.39	-0.94
Short Long Term Debt	0.72	0.32	0.71	0.72	0.71	-0.79	0.76	0.59	0.59	0.81	0.67	0.59	0.62	0.57	-0.6	0.49	0.88	0.67	0.22	0.82		0.62	0.55	0.49	-0.49	-0.72
Short Term Debt	0.43	-0.26	0.98	0.36	0.69	-0.89	0.93	0.4	0.4	0.8	0.76	0.41	0.94	0.58	-0.42	0.42	0.61	0.74	-0.19	0.63	0.62		0.42	0.32	-0.89	-0.81
Net Invested Capital	0.97	-0.28	0.57	0.95	0.93	-0.75	0.7	0.99	0.99	0.84	0.89	0.99	0.28	0.95	-0.99	0.92	0.85	0.85	0.03	0.9	0.55	0.42		0.99	-0.26	-0.85
Net Working Capital	0.95	-0.27	0.49	0.94	0.89	-0.68	0.62	0.98	0.98	0.79	0.85	0.98	0.2	0.92	-0.98	0.9	0.8	0.79	0.05	0.85	0.49	0.32	0.99		-0.19	-0.79
Intangible Assets	-0.25	0.18	-0.86	-0.22	-0.57	0.74	-0.81	-0.22	-0.22	-0.67	-0.59	-0.21	-0.95	-0.34	0.3	-0.16	-0.39	-0.47	0.13	-0.39	-0.49	-0.89	-0.26	-0.19		0.6
Retained Earnings Total Equity	-0.86	0.28	-0.9	-0.81	-0.94	0.97	-0.94	-0.84	-0.84	-0.97	-0.98	-0.85	-0.66	-0.92	0.84	-0.85	-0.9	-0.96	0.03	-0.94	-0.72	-0.81	-0.85	-0.79	0.6

Click cells to compare fundamentals

INmune Bio Account Relationship Matchups

INmune Bio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	24.5M	40.7M	99.9M	81.8M	57.0M	41.6M
Total Current Liabilities	700.4K	1.8M	4.4M	10.9M	18.5M	19.4M
Total Stockholder Equity	23.6M	38.8M	80.2M	60.1M	38.1M	33.6M
Net Tangible Assets	7.1M	22.2M	63.7M	43.6M	50.1M	52.6M
Retained Earnings	(21.3M)	(33.4M)	(63.7M)	(91.0M)	(121.0M)	(115.0M)
Accounts Payable	692.1K	1.6M	3.8M	5.2M	7.9M	8.3M
Cash	7.0M	22.0M	74.8M	52.2M	35.8M	23.6M
Cash And Short Term Investments	7.0M	22.0M	74.8M	52.2M	35.8M	23.6M
Capital Surpluse	44.8M	72.1M	143.9M	151.8M	174.6M	183.3M
Total Liab	860.5K	1.9M	19.7M	21.7M	18.9M	19.8M
Total Current Assets	7.8M	24.0M	82.6M	64.7M	39.9M	27.2M
Common Stock	8.7K	10.8K	13.5K	18K	817K	857.9K
Net Debt	(6.8M)	(21.8M)	(59.6M)	(36.8M)	(25.4M)	(26.7M)
Non Current Assets Total	16.7M	16.7M	17.3M	17.1M	17.1M	16.2M
Net Receivables	645.4K	1.8M	5.5M	8.5M	2.4M	2.8M
Common Stock Total Equity	8.7K	10.8K	13.5K	18K	20.7K	12.9K
Common Stock Shares Outstanding	10.3M	12.0M	16.1M	17.9M	18.0M	14.8M
Liabilities And Stockholders Equity	24.5M	40.7M	99.9M	81.8M	57.0M	46.8M
Non Current Liabilities Total	160.2K	126.3K	15.4M	10.8M	397.0K	377.1K
Other Current Assets	769.3M	2.0B	7.8M	4.0M	1.7M	1.6M
Other Stockholder Equity	44.9M	72.1M	143.9M	151.8M	158.3M	85.3M
Accumulated Other Comprehensive Income	(8.5K)	10.7K	1K	(699K)	(799K)	(759.1K)
Net Invested Capital	23.6M	38.8M	94.7M	74.8M	48.1M	49.4M
Net Working Capital	7.1M	22.2M	78.2M	53.8M	21.5M	29.0M
Retained Earnings Total Equity	(21.3M)	(33.4M)	(63.7M)	(91.0M)	(81.9M)	(77.8M)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:

How To Invest In INmune

Details

Is INmune Stock a good investment?

Details

What is INmune Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Complementary Tools for INmune Stock analysis

When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.

	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities

Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.67)

Revenue Per Share

0.009

Quarterly Revenue Growth

(0.71)

Return On Assets

(0.27)

Return On Equity

(0.61)

The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

INmune Other Assets vs Net Working Capital Analysis

Other Assets vs Net Working Capital

Other Assets vs Net Working Capital Correlation Analysis

Correlation Coefficient

Other Assets

Net Working Capital

INmune Bio fundamental ratios Correlations

INmune Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

INmune Bio fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for INmune Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Net Invested Capital	+ 0.99	Cash
Net Invested Capital	+ 0.99	Cash And Short Term Investments

Net Invested Capital	- 0.99	Net Debt
Net Debt	- 0.99	Cash And Short Term Investments
Net Debt	- 0.99	Cash
Accounts Payable	- 0.99	Retained Earnings
Net Working Capital	- 0.98	Net Debt
Net Debt	- 0.98	Total Current Assets